{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:56:11Z","timestamp":1789606571728,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Uveal melanoma (UM) is the most common primary ocular malignancy with a high rate of metastases. While immune checkpoint inhibitors (ICIs), including ipilimumab and nivolumab (ipi\u2005+\u2005nivo), have shown efficacy in metastatic cutaneous melanoma, their success in metastatic UM (MUM) remains limited. This study evaluates toxicity and outcomes of ipi\u2005+\u2005nivo in the largest, multicenter MUM cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed 131 MUM patients treated with ipi\u2005+\u2005nivo from 2016 to 2024 across 5 international centers. Rates of toxicity, response, and survival outcomes were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 131 patients, 37.4% of patients received 4 cycles of ipi\u2005+\u2005nivo. The most common reason for ipi\u2005+\u2005nivo discontinuation (31.3%) was toxicity. Of all treated patients, 80.2% experienced immune-related adverse events (irAEs). The overall response rate (ORR) was 16.4%, and the disease control rate (DCR) was 43.4%. Progression-free survival (PFS) was three months, and the median overall survival (OS) was 18 months. Patients receiving ipi\u2005+\u2005nivo as second-line therapy had lower ORR compared to patients who received ipi\u2005+\u2005nivo as first-line therapy (P\u2005=\u2005.04). Patients with exclusively extrahepatic metastases had a better ORR and OS compared to those with hepatic or mixed metastases (P\u2005=\u2005.02, P\u2005=\u2005.02, respectively). 20.6% of patients developed eosinophilia during treatment, which was associated with improved median OS (24 months vs 15 months, P\u2005=\u2005.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ipi\u2005+\u2005nivo shows moderate efficacy and clinically relevant toxicities in patients with MUM. Eosinophilia is a potential prognostic biomarker, that merits further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf173","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:26:59Z","timestamp":1750789619000},"source":"Crossref","is-referenced-by-count":6,"title":["Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4444-4412","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Ciernik","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Zurich , Zurich 8032 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ciernik","sequence":"additional","affiliation":[{"name":"BIFOLD, Technische Universit\u00e4t Berlin , Berlin 10587 ,","place":["Germany"]},{"name":"Hector Fellow Academy, Karlsruhe , Berlin 76131 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bonczkowitz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich , Munich 80337 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Morak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich , Munich 80337 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-3643","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich , Munich 80337 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine","family":"Bennaceur","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleigha","family":"Lawless","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston 02114 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf , Hamburg 20246 ,","place":["Germany"]},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf , Hamburg 20144 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf , Hamburg 20246 ,","place":["Germany"]},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf , Hamburg 20144 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Carter","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, Middlesex HA6 2RN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, Middlesex HA6 2RN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tschopp","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Zurich , Zurich 8032 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Zurich , Zurich 8032 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-8608","authenticated-orcid":false,"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Zurich , Zurich 8032 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2025070707213860900_CIT0001","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"2025070707213860900_CIT0002","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10555-017-9663-3","article-title":"The biology of uveal melanoma","volume":"36","author":"Amaro","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"2025070707213860900_CIT0003","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"2025070707213860900_CIT0004","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res."},{"key":"2025070707213860900_CIT0005","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41417-022-00558-y","article-title":"Novel treatment paradigms for metastatic uveal melanoma","volume":"29","author":"Patel","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"2025070707213860900_CIT0006","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med."},{"key":"2025070707213860900_CIT0007","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2024","journal-title":"N Engl J Med."},{"key":"2025070707213860900_CIT0008","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J ImmunoTher Cancer."},{"key":"2025070707213860900_CIT0009","doi-asserted-by":"publisher","first-page":"e000331","DOI":"10.1136\/jitc-2019-000331","article-title":"Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study","volume":"8","author":"Najjar","year":"2020","journal-title":"J ImmunoTher Cancer."},{"key":"2025070707213860900_CIT0010","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025070707213860900_CIT0011","doi-asserted-by":"publisher","first-page":"2116845","DOI":"10.1080\/2162402X.2022.2116845","article-title":"Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients","volume":"11","author":"Sala\u00fcn","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025070707213860900_CIT0012","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II Trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025070707213860900_CIT0013","doi-asserted-by":"publisher","first-page":"7887","DOI":"10.1038\/s41598-024-55675-5","article-title":"Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis","volume":"14","author":"Yamada","year":"2024","journal-title":"Sci Rep."},{"key":"2025070707213860900_CIT0014","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone vs ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"2025070707213860900_CIT0015","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/CMR.0000000000000900","article-title":"Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis","volume":"33","author":"Pham","year":"2023","journal-title":"Melanoma Res."},{"key":"2025070707213860900_CIT0016","doi-asserted-by":"publisher","first-page":"1395225","DOI":"10.3389\/fimmu.2024.1395225","article-title":"Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events","volume":"15","author":"Koch","year":"2024","journal-title":"Front Immunol."},{"key":"2025070707213860900_CIT0017","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41416-021-01310-3","article-title":"Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles","volume":"124","author":"Ye","year":"2021","journal-title":"Br J Cancer."},{"key":"2025070707213860900_CIT0018","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.3390\/cancers13236141","article-title":"Association between immune-related adverse events and survival in 319 stage IV melanoma patients treated with PD-1-Based immunotherapy: an approach based on clinical chemistry","volume":"13","author":"Serna-Higuita","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025070707213860900_CIT0019","doi-asserted-by":"publisher","first-page":"115053","DOI":"10.1016\/j.ejca.2024.115053","article-title":"Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome","volume":"212","author":"Jurlander","year":"2024","journal-title":"Eur J Cancer."},{"key":"2025070707213860900_CIT0020","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","volume":"86","author":"Mangan","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"2025070707213860900_CIT0021","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"key":"2025070707213860900_CIT0022","doi-asserted-by":"publisher","first-page":"1366081","DOI":"10.3389\/fonc.2024.1366081","article-title":"Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma","volume":"14","author":"Brand","year":"2024","journal-title":"Front Oncol."},{"key":"2025070707213860900_CIT0023","doi-asserted-by":"publisher","first-page":"eadp2442","DOI":"10.1126\/sciadv.adp2442","article-title":"Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth","volume":"10","author":"Artham","year":"2024","journal-title":"Sci Adv."},{"key":"2025070707213860900_CIT0024","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2025070707213860900_CIT0025","doi-asserted-by":"publisher","first-page":"FSO608","DOI":"10.2144\/fsoa-2020-0070","article-title":"A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy","volume":"6","author":"Krishnan","year":"2020","journal-title":"Future Sci OA."},{"key":"2025070707213860900_CIT0026","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12885-019-5384-z","article-title":"Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma","volume":"19","author":"Kr\u00fcckel","year":"2019","journal-title":"BMC Cancer."},{"key":"2025070707213860900_CIT0027","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.3390\/cancers14225676","article-title":"Activated eosinophils predict longer progression-free survival under immune checkpoint inhibition in melanoma","volume":"14","author":"Ammann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025070707213860900_CIT0028","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/cancers11060817","article-title":"Uveal melanoma: a european network to face the many challenges of a rare cancer","volume":"11","author":"Piperno-Neumann","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2025070707213860900_CIT0029","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.3390\/cancers13215316","article-title":"Radiological patterns of uveal melanoma liver metastases in correlation to genetic status","volume":"13","author":"Yavuzyigitoglu","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025070707213860900_CIT0030","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/cancers11101489","article-title":"Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma","volume":"11","author":"Bol","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2025070707213860900_CIT0031","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol."},{"key":"2025070707213860900_CIT0032","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp vs nivolumab plus ipilimumab in first line metastatic uveal melanoma: a propensity score weighted analysis","volume":"35","author":"Piulats","year":"2023","journal-title":"Ann Oncol."},{"key":"2025070707213860900_CIT0033","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1002\/cncr.34927","article-title":"Determinants of overall survival in patients with metastatic uveal melanoma","volume":"129","author":"Demkowicz","year":"2023","journal-title":"Cancer."},{"key":"2025070707213860900_CIT0034","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/cancers16193346","article-title":"Impact of metastatic pattern on survival in patients with posterior uveal melanoma: a retrospective cohort study","volume":"16","author":"Hindso","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025070707213860900_CIT0035","doi-asserted-by":"publisher","first-page":"961517","DOI":"10.3389\/fonc.2022.961517","article-title":"Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol."},{"key":"2025070707213860900_CIT0036","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"2025070707213860900_CIT0037","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.3390\/cancers15133430","article-title":"Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2025070707213860900_CIT0038","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.ejca.2024.115161","article-title":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors","volume":"214","author":"Dimitriou","year":"2024","journal-title":"Eur J Cancer."},{"key":"2025070707213860900_CIT0039","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.3390\/cancers13246390","article-title":"Combination of immune checkpoint inhibitors and liver-specific therapies in liver-metastatic uveal melanoma: can we thus overcome its high resistance","volume":"13","author":"Blomen","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025070707213860900_CIT0040","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s11684-023-0993-y","article-title":"Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial","volume":"17","author":"Koch","year":"2023","journal-title":"Front Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf173\/63571186\/oyaf173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf173\/63571186\/oyaf173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf173\/63571186\/oyaf173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:21:53Z","timestamp":1751887313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf173\/8173021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf173","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf173"}}